$1.55
0.00% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US0547544033
Symbol
AYTU

Aytu BioScience Inc Stock price

$1.55
-0.74 32.31% 1M
-1.51 49.35% 6M
-1.29 45.42% YTD
-0.74 32.31% 1Y
-47.45 96.84% 3Y
-164.45 99.07% 5Y
-2,220,536.05 100.00% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+0.00 0.00%
ISIN
US0547544033
Symbol
AYTU

Key metrics

Market capitalization $9.53m
Enterprise Value $7.61m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.10
P/S ratio (TTM) P/S ratio 0.13
P/B ratio (TTM) P/B ratio 0.32
Revenue growth (TTM) Revenue growth -25.89%
Revenue (TTM) Revenue $75.48m
EBIT (operating result TTM) EBIT $-1.53m
Free Cash Flow (TTM) Free Cash Flow $-2.50m
Cash position $20.11m
EPS (TTM) EPS $-1.22
P/E forward 6.74
P/S forward 0.14
EV/Sales forward 0.09
Short interest 3.92%
Show more

Is Aytu BioScience Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Aytu BioScience Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aytu BioScience Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aytu BioScience Inc:

Buy
100%

Financial data from Aytu BioScience Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
75 75
26% 26%
100%
- Direct Costs 29 29
34% 34%
38%
47 47
20% 20%
62%
- Selling and Administrative Expenses 38 38
34% 34%
51%
- Research and Development Expense 2.61 2.61
28% 28%
3%
6.17 6.17
290% 290%
8%
- Depreciation and Amortization 7.70 7.70
14% 14%
10%
EBIT (Operating Income) EBIT -1.53 -1.53
87% 87%
-2%
Net Profit -6.25 -6.25
74% 74%
-8%

In millions USD.

Don't miss a Thing! We will send you all news about Aytu BioScience Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aytu BioScience Inc Stock News

Neutral
Seeking Alpha
2 days ago
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q1 2025 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Robert Blum - IR, Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Outgoing Chief Financial Officer Ryan Selhorn - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2025 Q1 Ear...
Neutral
Accesswire
2 days ago
Net income of $1.5 million Adjusted EBITDA1 of $1.9 million ADHD Portfolio net revenue up 1% to $15.3 million Pediatric Portfolio net revenue up 54% sequentially $20.1 million cash balance at September 30, 2024 Organizational changes and operating optimization plan implemented to further streamline operations, reduce expenses, and accelerate path to consistent cash flow Ryan Selhorn promoted to...
Neutral
Accesswire
9 days ago
DENVER, CO / ACCESSWIRE / November 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its first quarter of fiscal 2025, after the market close on Wednesday, November 13, 2024. The Company has scheduled a conference call and webcast that same day, Wed...
More Aytu BioScience Inc News

Company Profile

Aytu BioScience, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Natesto, Tuzistram, ZolpiMist and MiOXSYS. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Head office United States
CEO John Donofrio
Founded 2002
Website www.aytubio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today